| Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) | Type/Product Area | Terms/Details (Date) |
| Bioniche Pharma (TSX:BNC) | Baxter Healthcare Corp. | Agreement under which Bioniche has acquired the Enlon product line, which is for the differential diagnosis of myasthenia gravis | Financial terms were not disclosed (7/2) |
| Cubist Pharmaceuticals Inc. (CBST) | AstraZeneca plc (UK) | Agreement to promote and support AstraZeneca's Merrem I.V. broad-spectrum antibiotic using its U.S. acute care sales force | The deal establishes a baseline of $20M in yearly revenue, which will be adjusted based on actual Merrem sales (7/2) |
| DOR BioPharma Inc. (OTC BB: DORB) | IDIS Ltd. (UK) | Agreement for the supply and distribution within the European Union of the company's investigational drug orBec (oral beclometh-asone dipropionate) for the treatment of gastro-intestinal graft-vs.-host disease via a named patient program | Terms were not disclosed (7/15) |
|
Notes: # The information in the chart does not cover agricultural agreements or those between biotech companies. * Private companies are indicated with an asterisk.Unless otherwise noted, stock symbols listed are on the Nasdaq market. OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | |||
